ELV Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -4.28%, SMA50 -7.82%, SMA200 -4.9%). The stock’s 14-day RSI is 38.45 (weak momentum), while the ATR of 11.63 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -29.58% below its high and over 18.03% above its low. Average 10-day trading volume of 1.98 million shares is in line with the 3-month average of 1.93 million, indicating normal recent market interest.

Elevance Health Inc. last paid a dividend of 6.85 per share, this equals a trailing yield of roughly 1.15%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $948.30. This means the shares are trading below this model’s fair value.

Elevance Health Inc. (NYSE:ELV) closed at $392.40 USD, losing -$3.81 (-0.96%) from the previous close of $396.21. The stock is currently within 5% of its 52-week high $273.71 and $408.00. With a market capitalization of about $85.21 billion, Elevance Health Inc. is classified as a large-cap and shows lower-than-market volatility (beta ~0.67). Key stats such as the average daily volume over the past year has been around 1.96 million shares, volume is running light vs its 52-week average. Headquartered in Indianapolis, IN, Elevance Health Inc. operates in the Healthcare sector and the Medical - Healthcare Plans industry. Led by CEO Gail Koziara Boudreaux, the company employs approximately 104,200 people and listed since October 30, 2001. Elevance Health Inc. operates as a health benefits company.

Elevance Health Inc. has 225.18 million shares outstanding. The public float is 224.66 million shares, elevated short interest at 1.26% of float. This equals 2.84 million shares. The short ratio is 0.92 days. Institutional investors hold 93.41% of the float. Insiders own 0.17%. BOUDREAUX GAIL holds 144.85 thousand shares, Gallina John E has 54.32 thousand shares and MCCARTHY GLORIA M has 51.44 thousand shares. Over the past six months, insider transactions show net selling. They sold 4.75 thousand shares across 3 transactions.

Elevance Health Inc. generated EPS of $25.11 over the past year. Five-year average earnings growth is 6.99%. Wall Street analysts project EPS growth of 5.12% annually over the next five years. The latest quarter delivered EPS of $12.58. The next quarter is forecast at $10.58. Next year's EPS is expected at $12.19. Analyst sentiment is bullish. Analyst rating data shows there are 25 Strong Buy ratings, 16 Buy ratings, 10 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $498.00 to $297.00. The high target offers 25.69% upside. The low target suggests -25.04% downside. The mean target is $389.37. This offers -1.73% upside. Elevance Health Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 22, 2026, missed forecasts by 14.05%. The prior quarter beat by 7.42%. Over the last six quarters, Apple has recorded several small beats. These include 1.05% in January 23, 2025.

Elevance Health Inc. trades at a P/E ratio of 16.58, slightly below the S&P 500 average, with a price-to-sales ratio of 0.43 and a price-to-book ratio of 1.98 suggesting the stock is closer to book value. The P/FCF stands at 13.27, also above market averages.

Elevance Health Inc. (NYSE:ELV) shares are flat 4.71% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Elevance Health Inc. trading at a premium to the broader market with a P/E of 16.58. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $462.94, suggesting 16.84% upside. Our AI forecast model points to short-term strength (9.04% over two weeks), a medium-term rise (48.84% over three months), and a longer-term loss (-15.21% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Elevance Health Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.04%, with price expected at $432.02 by June 03, 2026, within a range of $423.61 to $439.76 3-Month Outlook: Projected rise of 48.84%, reaching $589.72 by August 18, 2026, with a range of $550.59 to $626.41. 1-Year Outlook: Projected loss of -15.21%, with price at $335.93 by May 20, 2027, within a range of $314.84 to $355.43.